Last reviewed · How we verify
Safety group
At a glance
| Generic name | Safety group |
|---|---|
| Sponsor | Sinovac (Dalian) Vaccine Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment (NA)
- A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine (PHASE1)
- Inhaled Ciclesonide Study in Preterm Infants (PHASE1)
- A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus (PHASE1)
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (PHASE3)
- Vibrotactile Balance Belt Effect on Improving Gait (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Safety group CI brief — competitive landscape report
- Safety group updates RSS · CI watch RSS
- Sinovac (Dalian) Vaccine Technology Co., Ltd. portfolio CI